Dr. Reddy's Laboratories reported a strong Q3FY25 with consolidated revenues of Rs. 8,359 crores ($977 million), marking a 16% YoY growth driven by the newly acquired Nicotine Replacement Therapy business, which contributed Rs. 605 crores in revenue.